DBV Technologies | DBVT - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 279.64M 36.37M 2026-06
Alnylam Pharmaceuticals USD 992.69M 167.68M 2026-06
Amarin USD 23.17M 961K 2025-12
BioCryst Pharmaceuticals USD 214.41M 61.36M 2026-06
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
DBV Technologies USD 2.77M 33.21M 2025-09
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Incyte USD 1.57B 400.89M 2026-06
Insmed USD 356.19M 99.73M 2026-06
Ionis Pharmaceuticals USD 265M 22M 2026-06
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
United Therapeutics USD 683.8M 35.7M 2026-06